Literature DB >> 7572396

Long-term follow-up of HIV positive asymptomatic patients having received cyclosporin A.

R Levy1, J P Jais, J M Tourani, P Even, J M Andrieu.   

Abstract

The data of the 27 asymptomatic HIV-1 seropositive patients with CD4+ cell count between 300 and 600/microliters treated by Cyclosporin A (CSA) (7.5 mg/kg/day) in our institution between October 1985 and 1987 were reviewed in October 1993. Hemoglobin concentration, platelet count, total lymphocytes, CD4+ and CD8+ cell counts and serum core protein p24 antigenemia, as well as creatininemia measured before CSA onset, at CSA cessation and twice a year were recorded as well as clinical signs and CSA toxicities. In October 1993 median duration of CSA treatment was 11 months, median follow-up after CSA cessation was 45 months and median total follow-up was 67 months. Toxicities of CSA were those commonly encountered in other pathologies. Under CSA no patient progressed toward clinical AIDS (1987 definition). The mean CD4+ cell count of the 27 patients remained unchanged (gain of 1 cell/year) under CSA treatment, while it decreased at a rate of 50 cells/year after CSA cessation (p < 0,005). On the other hand CSA treatment had no significant impact on the evolution of total lymphocyte count, CD8+ cell counts, and P24 antigenémia.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7572396     DOI: 10.1007/978-1-4615-1995-9_20

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  9 in total

Review 1.  New uses for old drugs in HIV infection: the role of hydroxyurea, cyclosporin and thalidomide.

Authors:  E Ravot; J Lisziewicz; F Lori
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

Review 2.  Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection.

Authors:  S D Lawn; S T Butera; T M Folks
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

Review 3.  HIV-associated chronic immune activation.

Authors:  Mirko Paiardini; Michaela Müller-Trutwin
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

Review 4.  Rheumatoid arthritis in patients with HIV: management challenges.

Authors:  Matthew B Carroll; Joshua H Fields; Philip G Clerc
Journal:  Open Access Rheumatol       Date:  2016-04-29

Review 5.  HIV-Related Immune Activation and Inflammation: Current Understanding and Strategies.

Authors:  Tingxia Lv; Wei Cao; Taisheng Li
Journal:  J Immunol Res       Date:  2021-09-29       Impact factor: 4.818

6.  Long-term clinical, immunologic and virologic impact of glucocorticoids on the chronic phase of HIV infection.

Authors:  Jean-Marie Andrieu; Wei Lu
Journal:  BMC Med       Date:  2004-05-05       Impact factor: 8.775

7.  Mucosal SIV Vaccines Comprising Inactivated Virus Particles and Bacterial Adjuvants Induce CD8(+) T-Regulatory Cells that Suppress SIV-Positive CD4(+) T-Cell Activation and Prevent SIV Infection in the Macaque Model.

Authors:  Jean-Marie Andrieu; Song Chen; Chunhui Lai; Weizhong Guo; Wei Lu
Journal:  Front Immunol       Date:  2014-06-30       Impact factor: 7.561

8.  Oral disease-modifying antirheumatic drugs and immunosuppressants with antiviral potential, including SARS-CoV-2 infection: a review.

Authors:  Y C Tsai; T F Tsai
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-09-03       Impact factor: 5.346

Review 9.  A 30-year journey of trial and error towards a tolerogenic AIDS vaccine.

Authors:  Jean-Marie Andrieu; Wei Lu
Journal:  Arch Virol       Date:  2018-07-24       Impact factor: 2.574

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.